Literature DB >> 30825425

Exome sequencing identifies compound heterozygous KCTD7 mutations in a girl with progressivemyoclonus epilepsy.

Libin Mei1, Yanru Huang2, Jing Chen1, XueMei He1, Shaobin Lin3, Luying Liao3, XiaoYan Wang3, XianJing Huang1, Yanwei Sha1, Zhiyong Ji1, Ping Li4.   

Abstract

Progressive myoclonic epilepsies (PME) are a clinically and genetically heterogeneous group of rare diseases characterized by myoclonic seizures, tonic-clonic seizures, and neurological deterioration. Here, we genetically analyzed a Chinese patient affected by infantile-onset progressive myoclonic epilepsy. We applied next-generation whole exome capture sequencing with Sanger direct sequencing to the proband and her unaffected parents. Two compound heterozygous mutations were identified in the KCTD7 gene. The first mutation [c. 434A > G(p.Q145R)] was inherited from her father, while the second [c.631C > T(p.R211X)] was inherited from her mother. The two were co-segregated with disease phenotype in the family. To our knowledge, this is the first report of KCTD7 mutations causing PME in the Chinese population, with c. 434A > G in particular being a novel mutation. Our findings supported the important role of KCTD7 in PME and broadened the gene's mutation spectrum. Thus, this study contributes to genetic diagnoses and counselling of families with PME.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Compound heterozygous mutations; KCTD7; Progressive myoclonic epilepsies; Whole-exome sequencing

Mesh:

Substances:

Year:  2019        PMID: 30825425     DOI: 10.1016/j.cca.2019.02.028

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Kctd7 deficiency induces myoclonic seizures associated with Purkinje cell death and microvascular defects.

Authors:  Justine H Liang; Jonathan Alevy; Viktor Akhanov; Ryan Seo; Cory A Massey; Danye Jiang; Joy Zhou; Roy V Sillitoe; Jeffrey L Noebels; Melanie A Samuel
Journal:  Dis Model Mech       Date:  2022-09-13       Impact factor: 5.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.